| 2017-WATT-67867 | |
| According to a 2012 study by the American Pain Society, the annual cost of chronic pain in the United States is as high as $635 million, impacting more than 100 million people. According to the Centers for Disease Control and Prevention (CDC), 91 people die in the U.S. every day from an opioid overdose. Chronic and inflammatory pain are treated with antidepressants, anticonvulsants, and/or opioids. The use of opioids often leads to opioid dependence, which is treated with opioid substitutes such as methadone, buprenorphine, or opioid antagonists. There is a need for a treatment option for chronic and inflammatory pain that provides effective pain relief as well as eliminates opioid addiction and dependence. Researchers at Purdue University have developed compounds that may provide an effective method of treatment for chronic and inflammatory pain by inhibiting selective adenylyl cyclases, especially adenylyl cyclase 1. These compounds may also prevent and/or reduce opioid dependence. Advantages: -Chronic and inflammatory pain relief -Non-opioid -Non-addictive -Possibly treat opioid dependence Potential Applications: -Pain treatment -Opioid dependence treatment option Related Publication: Tarsis F. Brust et al., Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties Sci Signal. 2017 Feb 21;10(467). |
|
|
|
|
Jun 29, 2018
Utility Patent
United States
(None)
(None)
Jun 30, 2017
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization 1801 Newman Road West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |